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Abstract 
Docetaxel has been the standard first-line therapy in metastatic castration resistant prostate cancer. The survival 
benefit is, however, limited by either primary or acquired resistance. In this study, Du145 prostate cancer cells were 
converted to docetaxel-resistant cells Du145-R and Du145-RB by in vitro culturing. Next generation RNAseq was 
employed to analyze these cell lines. Forty-two genes were identified to have acquired mutations after the resistance 
development, of which thirty-four were found to have mutations in published sequencing studies using prostate can-
cer samples from patients. Fourteen novel and 2 previously known fusion genes were inferred from the RNA-seq data, 
and 13 of these were validated by RT-PCR and/or re-sequencing. Four in-frame fusion transcripts could be transcribed 
into fusion proteins in stably transfected HEK293 cells, including MYH9-EIF3D and LDLR-RPL31P11, which were spe-
cific identified or up-regulated in the docetaxel resistant DU145 cells. A panel of 615 gene transcripts was identified 
to have significantly changed expression profile in the docetaxel resistant cells. These transcriptional changes have 
potential for further study as predictive biomarkers and as targets of docetaxel treatment.
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Background
Most metastatic prostate cancers respond to androgen 
deprivation therapy (ADT) but eventually develop castra-
tion resistance and become metastatic castration resist-
ant prostate cancers (mCRPC) about 24–36 months after 
the treatment start (Harris et al. 2009; Attar et al. 2009; 
Watson et  al. 2010). mCRPC is the major cause of can-
cer death in prostate cancer patients. Median survival 
time of patients with mCRPCs is 16–18  months from 
the start of progression (Amaral et  al. 2012). Docetaxel 
chemotherapy can further prolong the median overall 
survival by 3–5  months (Galsky et  al. 2012). However, 
docetaxel resistance is a critical problem because half of 
patients will not respond to docetaxel treatment (intrin-
sic resistance), while the other half, which responds ini-
tially, become resistant ultimately (acquired resistance) 
(Tannock et al. 2004). Failure of docetaxel treatment has 
been thought to be caused by either intrinsic or acquired 
resistance.
Docetaxel is a member of taxane family and widely 
been used to treat mCRPC patients. Docetaxel induces 
cancer cell death by binding β-tubulin, stabilizing micro-
tubule assembly, suppressing dynamics of individual 
micro-tubules in G2-M phase tumor cells and preventing 
disassembly (Yvon et al. 1999; Eisenhauer and Vermorken 
1998). Despite a decade of clinical use, the mechanism of 
resistance to docetaxel has not been fully investigated 
and there are no clinically reliable biomarkers to pre-
dict the drug resistance. Limited data suggests that the 
resistance may be caused by the following mechanisms: 
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(1) decreased drug concentration due to high expression 
of drug export pump proteins ABCB1, ABCB4, ABCC1 
(Gottesman et al. 2002); (2) mutations in the drug targets 
(Berrieman et al. 2004); (3) inhibition of apoptotic path-
ways (Bhalla 2003); (4) altered expression profile of tubu-
lins or microtubule-associated proteins (MAPs) (Seve 
and Dumontet 2008; Verrills et  al. 2006). So far, only a 
few drugs have been developed with modest survival 
benefit in docetaxel resistant mCRPC.
This study applied next generation RNA sequenc-
ing (RNAseq) technology in combination with specific 
software (Ozsolak and Milos 2011) to determine gene 
expression changes, mutations and fusions in docetaxel 
sensitive cell lines versus docetaxel resistant cell lines. 
The comparison between these cell lines identified a 
panel of genes potentially involved in the development of 
docetaxel resistance. The clinical importance was further 
addressed by comparing with published RNA sequencing 
results in prostate cancer samples from patients.
Results
Mutations acquired in docetaxel resistant cell lines
We generated docetaxel resistant variants of Du145 pros-
tate cancer cells as described in M&M. We used tripli-
cates of each cell line (Du145, Du145-R and Du145-RB) 
for whole transcriptome RNA-sequencing and found 
4864 mutations totally (Additional file 1). We compared 
TaxR (docetaxel resistant) and TaxS (docetaxel sensi-
tive) cell lines to find mutations acquired after doc-
etaxel treatment. Only mutations, which were absent in 
TaxS (Du145) but present in all Du145-R triplicates and 
Du145-RB triplicates, were chosen as “stably acquired 
mutations”. Forty-two such mutations were identified 
(Table  1) and 4 randomly selected mutations were vali-
dated by PCR followed by SANGER sequencing (Fig. 1). 
By matching with previously published whole tran-
scriptome analyses, we could identify that 34 of these 
genes had mutations in prostate cancer samples from 
patients (Table  1) (Robinson et  al. 2015). For many 
genes, e.g. ABCB2, there are published data to support 
their importance in the development of drug resistance 
(Aberuyi et al. 2014; Rahgozar et al. 2014).
Fusion transcript detection and validation
ChimeraScan software was employed to find fusions 
from RNAseq data. Selecting gene–gene pairs supported 
by two or more unique alignment reads provided an 
initial list of 48, 75 and 66 fusion candidates in DU145, 
Du145-R and Du145-RB cell lines respectively (Addi-
tional file 2). We validated all fusion candidates that had a 
ChimeraScan score above 5 in at least 1 out of 3 cell lines. 
Of 16 fusion candidates selected (Table 2), 13 (81.25 %) 
were verified by Reverse Transcription PCR (RT-PCR) 
with primers covering the fusion break points (Addi-
tional file 3), and 5 of validated genes were further veri-
fied by Sanger sequencing in the Du145, Du145-R and 
Du145-RB cell lines (Fig. 2). Two gene fusions had been 
found by previous studies: UBE2L3-KRAS (Wang et  al. 
2011) expressed in all three cell lines and TAF15-AP2B1 
(http://54.84.12.177/PanCanFusV2/Fusions!fusion) spe-
cific expressed in Du145 (Additional file  3). The other 
fourteen fusions were novel discovered.
Figure 3a showed that all chromosomes were involved 
in gene fusion except chr 21 and chr Y. The two larg-
est fusion groups were distributed in chr1 (27, 14.3  %) 
and chr6 (44, 23.3  %), and most of the fusions were 
intra-chromosomal (26 out of 27 in chr1; 39 out of 44 
in chr6). Of the 16 chosen fusion candidates (3 of them 
could not be validated by PCR), 10 of them were com-
monly expressed in all 3 cell lines, one expressed only in 
TaxR cell line (MYH9-EIF3D) and 2 specifically in TaxS 
cell line (TAF15-AP2B1, VCL-ADK) (Table  2; Fig.  3b). 
Among 10 commonly expressed fusions, two were up-
regulated in TaxR cell lines compared to TaxS cell line 
(LDLR-RPL31P11, SRGAP2P2-SRGAP2). Eight out of 16 
were predicted to be in-frame suggesting their potential 
to produce functional fusion proteins (Table 2).
Four fusion candidates were validated by qPCR in 
Du145, Du145-R and Du145-RB cells, as well as at the 
protein level by western blot in plasmid transfected 
HEK293 cells (Fig. 3c, d), but their translation into pro-
tein could not be validated by western blot in Du145, 
Du145-R and Du145-RB cell lines.
Interestingly, when we validated the VCL-ADK fusion 
candidate by PCR, we found that there were two bands 
in the same PCR lane (Fig. 3e). Sanger sequencing results 
showed that both of the two bands were VCL-ADK 
fusions. The upper band was a fusion between VCL and 
ADK variant 1, 2 and 3, while the lower band was another 
fusion with ADK variant 4. Western blot showed that 
both fusions (VCL-ADK variant 1, 2, 3 and VCL-ADK 
variant 4) could be detected as protein in plasmid trans-
fected HEK293 cell lines (Fig. 3d).
Identification of stably up‑ or down‑regulated genes in the 
TaxR cell lines
Using gene expression of parental Du145 (TaxS) cells as 
a baseline, we identified 453 up-regulated and 473 down-
regulated genes in the Du145-R cells, and 483 up- and 
365 down-regulated genes in the Du145-RB cells (Addi-
tional file  4). In addition, we found 216 genes with sig-
nificantly different expression levels between DU145-RB 
and DU145-R. These 216 genes were presumably not 
related to the development of docetaxel resistance. By 
matching the three gene lists we further identified 615 
(329 up-regulated and 286 down-regulated) genes that 
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Table 1 Mutations acquired after docetaxel treatment
Gene Full name Mutation AA Type Non‑ 
synonymous
In prostate tumor 
samples?
GALE UDP-galactose-4-epimerase TTT G[G/A]C AAT Single AA change G > D Damaging Yes yes
KIAA1522 KIAA1522 Deletion Frameshift NA Yes yes
ATP5F1 ATP synthase, H + transport-
ing, mitochondrial Fo 
complex subunit B1
GCC AA[G/T] TGC Single AA change K > N Damaging Yes
ZNF669 Zinc finger protein 669 GAA [C/T]AG TGT Nonsense Q > * NA Yes yes
MDK Midkine (neurite growth-
promoting factor 2)
Deletion Frameshift NA –
DDX23 DEAD-box helicase 23 GCT G[A/T]C AAA Single AA change D > V Damaging Yes yes
SFSWAP Splicing factor, suppressor of 
white-apricot homolog
GAG [A/G]GG AGT Single AA change R > G Damaging Yes yes
TJP1 Tight junction protein 1 CCA C[G/A]T TTT Single AA change R > H Damaging Yes yes
CASC4 Cancer susceptibility candi-
date 4
AAT AT[G/A] CCT Single AA change M > I Damaging Yes
MRPL28 Mitochondrial ribosomal 
protein L28
CAG G[A/G]C CCC Single AA change D > G Damaging Yes yes
STUB1 STIP1 homology and U-box 
containing protein 1
ATC G[C/T]G AAG Single AA change A > V Damaging Yes yes
UQCRC2 Ubiquinol-cytochrome C 
reductase core protein II
ACA A[A/C]A GGA Single AA change K > T Damaging Yes yes
CHTF8 Chromosome transmission 
fidelity factor 8
CCC A[G/T]G TCA Single AA change R > M Damaging – yes
KLHDC4 Kelch domain containing 4 GAC G[T/C]G TAT Single AA change V > A Damaging Yes yes
SPATA20 Spermatogenesis associ-
ated 20
GTC [C/T]CT CAC Single AA change P > S Damaging Yes yes
SMAD4 SMAD Family Member 4 Deletion Frameshift NA Yes yes
LSM14A LSM14A MRNA processing 
body assembly factor
CAG T[C/T]C ATG Single AA change S > F Damaging Yes yes
CALM3 Calmodulin 3 (phosphorylase 
kinase, delta)
GGG [G/A]AG AAG Single AA change E > K NA Yes
MYADM Myeloid-associated differen-
tiation marker
TCC C[C/T]T CGG Single AA change P > L Damaging Yes yes
ODC1 Ornithine decarboxylase 1 CAT G[T/C]G GGT Single AA change V > A Damaging Yes yes
FOSL2 FOS like antigen 2 GAC [C/A]TG CAG Single AA change L > M Damaging Yes yes
CYBRD1 Cytochrome B reductase 1 TTC [G/A]GG GCC Single AA change G > R Damaging Yes
BOK BCL2-related ovarian killer GAC [T/C]GT GTG Single AA change C > R Damaging Yes
ITCH Itchy E3 ubiquitin protein 
ligase
AAT G[G/A]T GAA Single AA change G > D Damaging Yes yes
DIP2A Disco interacting protein 2 
homolog A
AAC [G/A]TC TTC Single AA change V > I Damaging Yes yes
BID BH3 interacting domain 
death agonist
ACC [G/A]TA GCA Single AA change V > I Damaging Yes yes
NUP210 Nucleoporin 210 kDa ATA [G/T]CC TAC Single AA change A > S Damaging Yes yes
HYAL2 Hyaluronoglucosaminidase 2 CTG [C/T]GA CCT Nonsense R > * NA Yes
RBM15B RNA binding motif protein 
15B
ACC CA[G/T] CTG Single AA change Q > H Damaging Yes yes
CTBP1 C-terminal binding protein 1 TCC A[C/T]G CAG Single AA change T > M Damaging Yes yes
TACC3 Transforming acidic coiled-
coil containing protein 3
AGC T[C/T]T TCC Single AA change S > F Damaging Yes yes
AFAP1 Actin filament associated 
protein 1
TCA [G/C]AG GCC Single AA change E > Q Damaging Yes yes
MCTP1 Multiple C2 and transmem-
brane domain containing 1
ATG G[G/T]C TCA Single AA change G > V Damaging Yes yes
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were shared by both DU145-R and DU145-RB as com-
pared with DU145 (Additional file 4). These genes were 
thought to have stable expression changes after acquiring 
resistance to docetaxel. Of the 615 genes, the 40 most up- 
and down-regulated in the TaxR cell lines were chosen 
for verification by RT-PCR and 37/40 (92.5 %) were con-
firmed (Additional file 5).
Information about the most-differentially-expressed 
genes is shown in Additional file  6. The second most 
up-regulated gene was ABCB1, which encodes an ATP-
dependent drug efflux pump that mediates the devel-
opment of resistance to anticancer drugs (Gottesman 
et  al. 2002). The average fold changes (log) in TaxR cell 
lines were up to 8.9 and 10.2 in up-regulated genes and 
down-regulated genes, respectively. The largest func-
tional group was transcription factors (Additional file 7). 
Twenty-one oncogenes and 16 translocated cancer genes 
were also among the enriched functional groups in the 
set of 615 stably differentially-expressed genes.
The 615 most significantly deregulated genes were 
put into the Panther Online tool (www.pantherdb.org), 
which yielded 528 functional hits distributed on 11 GO-
terms, where the two largest groups were Binding (GO: 
0005488) and Catalytic Activity (GO: 0003824) (Fig. 4b). 
Thomson Reuters was employed to analyze enriched 
networks of expression changing genes and showed that 
the NF-κb, EGR1 (Early Growth Response 1) and ETS 
(ETS family of transcription factors) were the three most 
enriched networks in the docetaxel resistant cells (Fig. 4c 
and Additional file  8). PLAU and PLAUR (Plasminogen 
Activator, Urokinase Receptor), a ligand—membrane 
receptor pair, are the only ‘Convergence hubs’ and MDR1 
(ABCB1) was connected to all three pathways.
Next generation sequencing data of PC3 and LNCaP, 
two docetaxel-sensitive cell lines similar to Du145, were 
added into further analysis. Multivariate modeling with 
SIMCA resulted in a model, which separated all TaxS and 
TaxR cell lines into two classes and extracted those genes 
that contributed most to the model (Table 3).
When comparing the list of 615 stably up- or down-
regulated gene lists with the fusion gene list, we 
found 6 genes in common (Table  4), all of which were 
up-regulated.
Methods
Prostate cancer cell lines
Table 5 summarizes the prostate cancer cell lines used in 
this study. LNCaP, PC3 and DU145 cell lines were origi-
nally ordered from the ATCC (American Type Culture 
Collection). Du145 was cultured in medium containing 
docetaxel (from low concentration to high concentration, 
increased gradually) for one year, until Du145 acquired 
docetaxel resistance (Du145-R). We also cultured Du145-
R in normal medium without docetaxel for one month 
(Du145-RB) to see if it would revert to docetaxel sensi-
tive again (Kharaziha et al. 2015). DU145-RB was frozen 
Mutation and amino acid changing were showed in column 3 and 4. Mutation Type was analyzed by program SIFT and gained by setting cutoff as 0.05. ‘Damaging’ 
means that the substitution is predicted to affect protein function. NA not analyzed. The last column shows the connection between cell lines and tumor samples. It is 
labeled “yes” if mutation can be found in both cell line sequence and tumor sample sequence
Table 1 continued
Gene Full name Mutation AA Type Non‑ 
synonymous
In prostate tumor 
samples?
MAN2A1 Mannosidase alpha class 2A 
member 1
CTT A[T/A]C CAG single aa change I > N Damaging Yes yes
C5orf15 Chromosome 5 open reading 
frame 15
Deletion Frameshift NA Yes
UIMC1 Ubiquitin interaction motif 
containing 1
GAA G[C/A]T AGG Single AA change A > D Damaging Yes yes
MAML1 Mastermind like transcrip-
tional coactivator 1
Deletion Frameshift NA Yes yes
C6orf141 Chromosome 6 open reading 
frame 141
CGG [G/T]GG CCT Single AA change G > W Damaging Yes yes
CROT Carnitine O-octanoyltrans-
ferase
TTT [T/C]CC AAA Single AA change S > P Damaging Yes yes
CAPZA2 Capping actin protein of 
muscle Z-line alpha subunit 
2
AGG A[A/C]G GAG Single AA change K > T Damaging Yes yes
ASB6 Ankyrin Repeat and SOCS 
box containing 6
AAC [C/T]GC TTC Single AA change R > C Damaging Yes yes
ABCA2 ATP binding cassette subfam-
ily a member 2
GGC C[G/A]C TTC Single AA change R > H Damaging Yes yes
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after one month cultured without docetaxel. Every time 
when we needed to use DU145-RB, we would thaw and 
culture it in normal medium (without docetaxel) and the 
culture time would not extend 4 weeks. While, DU145-
R cells were always cultured in medium with 1000 ng/ml 
docetaxel. DU145, PC3 and LNCaP cells were cultured in 
medium without docetaxel.
RNAseq
Total RNA from prostate cancer cell lines was isolated 
by TRIzol (Invitrogen, Catalog #15596018) and extracted 
by subsequent phenol/chloroform. RNase-free DNase 
set (Qiagen, Catalog #79254) was used to remove DNA 
by DNase digestion. RNA quality was controlled by RNA 
Integrity Number (RIN) analysis by Agilent 2100 Bio-
analyzer System. Total RNA samples were sent to SciL-
ifeLab, Stockholm, Sweden and polyA selection was 
done at SciLifeLab. Samples were clustered on cBot and 
sequenced on HiSeq  2000 according to manufacturer’s 
instructions. Between 16.0 and 76.3 million reads were 
obtained per sample sequenced on HiSeq 2000.
Variant calling method
Removal of PCR duplicates was performed with Pic-
ard (picard.sf.net). After that the reads were extracted 
from bam file, imported into CLC Genomics workbench 
(CLC, Aarhus, Denmark) and aligned to the human ref-
erence genome (build 37p5) using Large Gap Read Map-
ping. Variant calling was conducted using Probabilistic 
Variant Detection tool within CLC Genomics workbench. 
The following criteria were applied for variant calling: (1) 
ignore non-specific matches, (2) Minimum coverage, and 
(3) Variant probability 90. The variations were filtered out 
if detected in any of 190 control exomes from non-can-
cer patients, or were dbSNP v137 reported SNPs, with a 
population frequency higher than 1 % in dbSNP v137. The 
Fig. 1 Mutation list validated by PCR followed by Sanger sequencing. Black arrow shows the mutation positions
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variants were annotated according to their overlap with 
genes and transcripts (UCSC, refSeq at http://genome.
ucsc.edu/, and Sanger cancer census gene at http://cancer.
sanger.ac.uk/cancergenome/projects/census/), conserva-
tion scores (UCSC), segmental duplications (UCSC), exon 
number, splice sites, amino acid change, cosmic database 
v63, ClinVar (a database of mutations and their clinical 
relevance at ftp://ncbi.nlm.nih.gov/pub/clinvar/), dbSNP 
v137 and predictions from Provean (http://provean.jcvi.
org), Sift (http://sift.jcvi.org) and Polyphen (http://genet-
ics.bwh.harvard.edu/pph2/bgi.shtml).
Analysis of differentially expressed genes
We analyzed RNAseq data according to a published 
TopHat and Cufflinks protocol (Trapnell et  al. 2012). In 
summary, we used TopHat to align reads to the reference 
genome, Cufflinks to assemble and obtain expression 
values for all transcripts, Cuffdiff for testing differen-
tial expression of genes and transcripts and finally the 
CummeRbund R package for downstream analysis and 
visualization.
Fusion detection method
We used ChimeraScan, which aligns paired-end reads 
to a reference genome-transcriptome with Bowtie in 
an iterative process where read pairs that could not be 
aligned were trimmed into smaller fragments and rea-
ligned (Iyer et  al. 2011). ChimeraScan uses a filter to 
avoid false-positive chimeras.
Statistical analysis
The online services Panther (http://www.pantherdb.
org) and Thomson Reuters were applied for functional 
enrichment analysis (Mi et  al. 2013; Huber-Keener 
et  al. 2012). Fusion transcripts from Du145, Du145-R 
and Du145-RB were visualized by Circos online (http://
mkweb.bcgsc.ca/tableviewer) (Krzywinski et  al. 2009). 
OPLS-DA model was established by SIMCA software, 
Table 2 Fusion transcripts identified by NGS and validated by PCR
5′ end genes and their information were listed in column 1 and 2, and 3′ end genes in column 3 and 4. Read Through, new fusion gene can be read through when 
translated. Intrachromosomal, fusion partners come from same chromosomes. Interchromosomal, fusion formed between different chromosomes. Last column was 
marked ‘Yes’ if fusions can be verified in Du145, Du145-R or Du145-RB
5′ gene (full name) 5′ chr 3′ gene (full name) 3′ chr Type Verified Express in TaxS Express in TaxR
TAF15 (TATA-box binding pro-
tein associated factor 15)
17 AP2B1 (adaptor related protein 
complex 2 beta 1 subunit)
17 Read through Yes Yes No
VCL (vinculin) 10 ADK (adenosine kinase) 10 Read through Yes Yes No
MYH9 (myosin, heavy chain 9, 
non-muscle)
22 EIF3D (eukaryotic translation 
initiation factor 3 subunit D)
22 Read through Yes No Yes
C14orf166 (chromosome 14 
open reading frame 166)
14 SLC25A21 (solute carrier family 
25 member 21)
14 Intra chromosomal Yes Yes Yes
UBE2L3 (ubiquitin conjugating 
enzyme E2 L3)
22 KRAS (kirsten rat sarcoma viral 
oncogene homolog)
12 Inter chromosomal Yes Yes Yes
LDLR (low density lipoprotein 
receptor)
19 RPL31P11 (ribosomal protein 
l31 pseudogene 11)
15 Read through Yes Yes Yes (up regulated)
IGSF9B (immunoglobulin 
superfamily member 9B)
11 FAM177A1 (family with 
sequence similarity 177 
member A1)
14 Inter chromosomal No
CTSD (cathepsin D) 11 IFITM10 (interferon induced 
transmembrane protein 10)
11 Read through Yes Yes Yes (up regulated)
FLJ39739 1 BC065231 1 Intra chromosomal Yes Yes Yes
LOC100286793 1 BC065231 1 Intra chromosomal Yes Yes Yes
UBE2H (ubiquitin conjugating 
enzyme E2 H)
7 WIZ (widely interspaced zinc 
finger motifs)
19 Inter chromosomal No
SFPQ (splicing factor proline/
glutamine-rich)
1 AL831889 (LOC100996496) 1 Read through Yes Yes Yes
CADM4 (cell adhesion mol-
ecule 4)
19 ZNF428 (zinc finger protein 
428)
19 Read through Yes Yes Yes
GOLT1A (golgi transport 1A) 1 KISS1 (KiSS-1 metastasis-
suppressor)
1 Read through Yes Yes Yes
SRGAP2P2 (SLIT-ROBO Rho 
GTPase activating protein 2B)
1 SRGAP2 (SLIT-ROBO Rho 
GTPase activating protein 2)
1 Intra chromosomal Yes Yes Yes (up regulated)
BTNL8 (butyrophilin like 8) 5 HMGA1 (high mobility group 
AT-Hook 1)
6 Inter chromosomal No
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and 2 classes (TaxS and TaxR) were set in the model to 
obtain VIP scores by whichvariables (genes) are sorted 
based on importance (contribution to the model) of 
genes (Bylesjo et al. 2006).
PCR and qPCR validation
Total RNA was isolated from cell lines by TRIzol (Invit-
rogen, Catalog #15596018) according to the manufac-
turer’s instructions. Cloned AMV First-Strand Synthesis 
Kit (Life Technologies, Catalog #12328) was used to tran-
scribe mRNA to cDNA.
PCR primers for fusion validation were designed 
according to the sequence of fusion transcripts. Forward 
primer was located on the 5′ gene of the fusion gene and 
reverse primer on the 3′ gene of the fusion gene. Primers 
for validation of mutations covered mutation points. PCR 
was conducted using Platinum Taq DNA polymerase 
(Life Technologies, Catalog #10966018) and was followed 
by Sanger sequencing (conducted by Eurofins Genom-
ics). To differentiate gene expression levels of selected 
genes, 20–32 amplifying cycles were used based on gene 
expression level.
Fig. 2 Sanger-sequencing validation of 5 fusion candidates discovered by NGS. Black lines indicates the fusion points between 2 genes
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qPCR primers for fusion validation were purchased 
from Applied Biosystems (Custom plus TaqMan RNA 
Assays). LightCycler 480 Probes Master was used 
combined with TaqMan primer on LightCycler 480 
instrument from Roche according to manufacturer’s 
instructions.
Plasmid construction and western blot validation
PCR product was ligated into multiple cloning sites of 
pCMV-AC-GFP after digestion of restriction enzymes, 
Sgf I and Mlu I. pCMV-AC-GFP was purchased from 
ORIGENE (Catalog #PS100010), Sgf I enzyme from 
NEB (Catalog #R0630S), Mlu I enzyme from NEB (Cat-
alog #R0198S), and T4 ligase from Promega (Catalog 
#M180A). We transfected HEK293 cells with constructed 
plasmid 48 h before collecting cells in lysis buffer. West-
ern blot experiments were conducted using these cell 
lysates. Anti-TurboGFP antibody was purchased from 
Evrogen (Catalog #AB513).
Discussion
We have identified 42 genes with specific and stable 
mutations in TaxR cells. The functions of these genes 
may support their importance in the development of 
docetaxel resistance. Among these genes, SMAD4 is 
a co-activator and mediator of signal transduction by 
TGF-beta and acts as a tumor suppressor. Experiments 
have shown that SMAD4 inactivation promotes drug 
Fig. 3 Landscape and validation of fusion candidates. a Circos plot of the genomic landscape of gene fusions discovered by RNAseq. b Venn 
diagram analysis of 13 fusions which could be validated by PCR. c qPCR validation of fusions in Du145, Du145-R and Du145-RB. d Fusion proteins 
detected in transfected HEK293 cells by Western blot. e Two different fusion transcript types, that is between VCL-ADK variants 1, 2, 3 and VCL-ADK 
variant 4
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Fig. 4 NGS analysis in TaxS and TaxR prostate cancer cell lines identifies gene expression changes and pathway networks involved in docetaxel 
resistance. a Venn diagram of overlap of significantly differently regulated genes by matching 3 gene lists. b Pie chart of 615 genes with stable gene 
expression changes in TaxR cells lines by Panther (www.pantherdb.org). c GeneGo (Thomsom Reuters) network analysis of the most deregulated 
genes in TaxR cell lines
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resistance in cancer (Zhang et al. 2014; Raz et al. 2014). 
ABCA2 is a member of ATP-binding cassette (ABC) 
transporters that transports many kinds of small mol-
ecules through membranes and is involved in drug resist-
ance in leukemia cell lines (Dharmapuri et al. 2015).
Approximately 50  % of prostate cancer has primary 
resistance to docetaxel treatment. The other half is 
sensitive to docetaxel but eventually develops second-
ary (acquired) resistance (Marin-Aguilera et al. 2012). In 
this study, 34 out of the 42 mutations discovered in the 
resistant cell lines can be found in tumor samples from 
patients (Table 1), implicating that primary and acquired 
resistance may share the same molecular mechanism(s). 
In the case of primary resistance, most cancer cells 
carry the resistant genomic changes before the treat-
ment, whereas for acquired resistance, just a few cancer 
cells carry these resistant genomic changes before treat-
ment. By treatment selection or new mutational events, 
most cancer cells become carriers of resistant genomic 
changes. This hypothesis can be further tested in studies 
using tumor samples from patient cohorts with data of 
docetaxel treatment.
The four fusion transcripts (listed in Fig.  3c: MYH9-
EIF3D, LDLR-RPL31P11, TAF15-AP2B1, VCL-ADK) 
could be detected by PCR and qPCR in the cell lines, 
but their translation into protein could not be vali-
dated by western blot in Du145, Du145-R and Du145-
RB, probably due to the low expression of the fusion 
proteins. Fusion transcripts could be translated into 
protein in stably transfected HEK293 cells analyzed by 
western blot. Moreover, several genes involved in the 
fusion events have shown important functions in can-
cer development. TAF15, a member of the FET family, 
has been found rearranged with various transcription 
factors with cancer promoting functions in sarcomas 
as well as in rare hematopoietic and epithelial cancers 
(Kovar 2011). MYH9 is a member of the myosin super-
family and its function is related to migration, invasion 
and metastasis of cancer cells. EIF3D is associated with 
cell cycle regulation and motility of prostate cancer 
cells (Gao et al. 2015). MYH9 fusion proteins have been 
found in anaplastic large cell lymphoma and one exam-
ple is the MYH9-ALK fusion protein that has tyrosine 
kinase activity in vivo (Lamant et al. 2003). The MYH9-
USP6 detected by a previous study and MYH9-EIF3D 
found in the present study have the same fusion point 
in MYH9. MYH9, which is located in the 5′ part of the 
Table 3 Genes contributed most to separate prostate can-
cer cell lines into TaxR and TaxS classes
M1.VIPpred, score shows the contribution to the SIMCA model. All 9 genes in 
this table were up-regulated in the TaxR cells
Gene symbol Full name M1.VIPpred
ABCB1 ATP-binding cassette, sub-family B (MDR/
TAP), member 1
1.48587
GPSM2 G-protein signaling modulator 2 1.48037
IL31RA Interleukin 31 receptor A 1.47976
LIMK1 LIM domain kinase 1 1.47921
GRK5 G protein-coupled receptor kinase 5 1.47789
SKAP1 Src kinase associated phosphoprotein 1 1.47782
ST6GALNAC5 Sialyltransferases 1.4765
C9orf125 Transmembrane protein 246 1.47636
ICAM1 Intercellular adhesion molecule 1 1.47543
Table 4 Fusion genes whose expression levels were also 
up-regulated in TaxR cell lines
Fold up-regulation, log2 fold expression change of genes in column 1 comparing 
TaxS cell line and TaxR cell lines















HMGA1 High mobility 
group AT-
hook 1















3.9 LDLR Low density 
lipoprotein 
receptor
VCL Vinculin 2.3 ADK Adenosine 
kinase
VIM Vimentin 4.9 SYCP1 Synaptonemal 
complex 
protein 1
Table 5 Prostate cancer cell lines which were analyzed 
by whole transcriptome sequencing
Androgen-dependent, cell line is sensitive to hormone treatment (Yes) or not 
(No). Docetaxel-sensitive, cell line is sensitive to docetaxel (Yes) or not (No). 
Triplicates, all cell lines were triplicates when sent to be sequenced
Cell line Androgen‑dependent Docetaxel‑sensitive Triplicates
LNCaP Yes Yes Yes
PC3 No Yes Yes
DU145 No Yes Yes
DU145-R No No Yes
Du145-RB No No Yes
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fusion product, functions as a regulator to manipulate 
gene expression and function of USP6, as well as EIF3D 
(Erickson-Johnson et al. 2011). These functional implica-
tions may encourage further verification by using tumor 
samples from the patients.
When we compared the expression of DU145-RB 
and DU145-R, we found 216 genes that were differ-
ently expressed. We tested that DU145-RB was still 
docetaxel resistant, indicating these genes were not 
involved in maintaining docetaxel resistance of the two 
resistant cell lines. As expected, ABCB1 (MDR1) was 
confirmed as one of the top 10 differentially expressed 
genes that could separate TaxR from TaxS cells. Its func-
tional importance was further supported by its connec-
tion with the NF-κb, EGR1 and ETS pathways (Fig.  4). 
ABCB1, which shows overexpression in some cancers, is 
involved in a common resistance mechanism. However, 
limited studies showed significant connection between 
ABCB1 and clinical outcomes, such as survival (Shaffer 
et al. 2012), indicating the importance of other molecu-
lar and biological changes. Researchers and pharmaceu-
tical companies are trying to circumvent this strategy 
and find new potential genes or pathways to overcome 
resistance in cancer.
TGPSM2 and GRK5 are members of G-protein sign-
aling pathway important in cancer progression. SKAP1 
encodes a src kinase associated phosphoprotein 1 and is a 
member of the Ras signaling pathway and B cell receptor 
signaling pathway. LIMK1 is a serine/threonine kinase 
associated with the cytoskeletal structure in many cellu-
lar processes, and may have importance in the sensitivity 
of lung cancer and osteosarcoma cells to chemotherapy 
treatment (Chen et al. 2013; Zhang et al. 2011). The anal-
ysis further showed that PLAU and PLAUR (Plasmino-
gen Activator, Urokinase Receptor), a pair of ligand and 
membrane receptor, constituted the only ‘Convergence 
hub’ by statistical analysis using the Thomson Reuters 
software. This novel finding may suggest that they may 
play a unique role in docetaxel resistance. It would be 
interesting to further study if they alone or, together with 
other important genomic findings in this study, can be 
further verified as important biomarkers to predict pri-
mary docetaxel resistance. Most importantly, they can 
even become attractive targets for the development of 
new drugs to overcome both primary and acquired doc-
etaxel resistance.
Conclusion
The present study found both previous and novel muta-
tions, genes with altered expression levels, and fusion 
proteins in docetaxel resistant prostate cancer cell lines, 
and provide some understanding of acquired docetaxel 
resistance at the gene transcription level. If some of these 
changes can be further verified with importance in pri-
mary resistance, they can be considered as predictive 
biomarkers for docetaxel treatment as well as targets for 
the development of new treatments to overcome the doc-
etaxel resistance.
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